menu ☰
menu ˟

Positive phase 3 trial results for potential first-in-class oral diabetes drug

01 Jul 2019
Top-line results from the TIMES 3 study demonstrate the experimental oral diabetes drug imeglimin achieved its primary safety and efficacy endpoints, according to a press release from Poxel and Sumitomo Dainippon Pharma Co.Imeglimin is an oxidative p...

Click here to view the full article which appeared in Endocrinology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.